HOME > NATIONAL > Article

Text Size

small

medium

large


Japan Bio Startup Seeks Approval of Heart Cell Sheets

Japan Bio Startup Seeks Approval of Heart Cell Sheets

   Tokyo, April 9 (Jiji Press)--A Tokyo-based biotechnology startup derived from the University of Osaka has applied for the health ministry's approval of production and sales of its heart cell sheets created from induced pluripotent stem cells.
   What is believed to be the first approval application for a regenerative medicine product in Japan was filed Monday by Cuorips Inc., where Yoshiki Sawa, specially appointed professor at the university, is serving as technology chief.
   In a world first, Sawa and colleagues transplanted in an ischemic cardiomyopathy patient 0.1-millimeter-thick, 4- to 5-centimerter-diameter sheets of heart cells made out of iPS cells generated from cells that were not the patient's in January 2020. The team had conducted similar operations on eight patients in total by March 2023 and confirmed the safety of the method and improvements in their symptoms.
   Describing Cuorips' move as "a giant step," Sawa vowed to "make efforts to save people in all corners of the world."

To read a full story, please click here to find out how to subscribe.

NATIONAL

HEADLINES

POLITICS
Japan's Prime Minister, Chief of Rengo to Meet Monday for 1st Time in 16 Years
ECONOMY
Japan Aiming to Increase Rice Exports by Eightfold in 2030 from 2024 Level
SPORTS
Women's Gymnastics: "Okamura," 2 Other New Uneven Bars Skills Officially Named
OTHER
Skymark Airlines to Allow Flight Attendants to Wear Sneakers on Duty from Mon.

AFP-JIJI PRESS NEWS JOURNAL


Photos